Table 2.
Frequency/(%) of patients exhibiting severity scores for tacrolimus adverse effects 18
| Adverse effects ratio | Absence | Low | Moderate | High |
|---|---|---|---|---|
| Cumulative | 5/7.5 | 18/26.9 | 36/53.7 | 8/11.9 |
| Range of ratio score (0–0.34) | (0) | (0.03–0.09) | (0.125–0.22) | (0.25–0.34) |
| Gastro‐intestinal | 16/23.9 | 13/19.4 | 31/46.3 | 7/10.4 |
| Range of ratio score (0–0.7) | (0) | (0.1–0.2) | (0.1–0.4) | (0.5–0.7) |
| Neurological | 15/22.4 | 20/30 | 21/31.3 | 11/16.4 |
| Range of ratio score (0–0.57) | (0) | (0.14) | (0.28) | (0.43–0.57) |
| Cosmetic | 38/56.7 | 21/31.3 | 4/6.0 | 4/6.0 |
| Range of ratio score (0–0.5) | (0) | (0.08) | (0.16) | (0.25–0.5) |
| Adverse effects | 0 | 1+ | 2+ | 3+ |
|---|---|---|---|---|
| Vomiting | 60/89.6 | 7/10.4 | 0/0.0 | NA |
| Diarrhoea | 44/65.7 | 15/22.4 | 8/11.9 | NA |
| Dyspepsia | 25/37.3 | 3/4.5 | 34/50.7 | 5/7.5 |
| Acid suppressive therapy | 28/41.8 | 35/52.2 | 4/6.0 | NA |
| Tremor | 33/49.3 | 31/46.3 | 3/4.5 | 0/0.0 |
| Headache | 55/82.1 | 12/17.9 | NA | NA |
| Insomnia | 34/50.7 | 16/23.9 | 16/23.9 | 1/1.5 |
| Acne a | 56/83.6 | 9/13.4 | 2/3.0 | 0/0.0 |
| Skin changes | 54/80.6 | 11/16.4 | 1/1.5 | 1/1.5 |
| Hirsutism | 58/86.6 | 8/11.9 | 0/0.0 | 1/1.5 |
| Gingival hyperplasia | 62/92.5 | 5/7.5 | 0/0.0 | NA |
| Myopathy | 54/80.6 | 12/17.9 | 1/1.5 | 0/0.0 |
| Post‐transplant diabetes mellitus | 64/95.5 | 3/4.5 | NA | NA |
| Lipids | Normal values | High values b | ||
|---|---|---|---|---|
| Total cholesterol (mg dl –1 ) | < 200 | 64/95.5 | > 200 | 3/4.5 |
| LDL (mg dl –1 ) | <100 | 52/77.6 | >100 | 15/22.4 |
| HDL (mg dl –1 ) | >60 | 16/23.9 | <60 | 51/76.1 |
| Triglycerides (mg dl –1 ) | <200 | 57/85.1 | >200 | 10/14.9 |
NA, not applicable since no rating
HDL, high‐density lipoprotein; LDL, low‐density lipoprotein
a
No patients exhibited a 4+ for acne
b
Lipids were categorized based upon the values considered as potential risk: > 200 mg/dl from total cholesterol and triglycerides, > 100 mg dl–1 for LDL and < 60 mg dl–1 for HDL 36
Permission granted for reproduction of Table 1 from Venuto R, Meaney C, Chang S, Leca N, Consiglio J, Wilding G, et al. Association of extrarenal adverse effects of posttransplant immunosuppression with sex and ABCB1 haplotypes. Medicine 2015; 94: e1315